美国不同种族和民族及10年ASCVD风险的他汀一级预防使用率
该研究基于2013年至2020年3月NHANES数据,纳入40-75岁无ASCVD、糖尿病且LDL-C<190 mg/dL的3417名参与者,评估他汀一级预防使用率。结果显示总体使用率低,黑人(20.0%)和西班牙裔(15.4%)低于白人(27.9%),且在最高风险层中黑人(23.8%)和西班牙裔(23.9%)仍显著低于白人。
要点
- 他汀一级预防使用率在所有种族和风险层中均低。
- 黑人和西班牙裔使用率显著低于白人,亚裔与白人相当。
- 最高风险层中黑人和西班牙裔使用率仍显著低于白人。
核心结论
- 他汀用于ASCVD一级预防在所有种族和民族中均低,黑人和西班牙裔成人使用率最低。
- 改善医疗可及性可能促进黑人和西班牙裔成人公平使用一级预防他汀。
研究设计与样本
- 研究为系列横断面分析,使用2013年至2020年3月NHANES数据。
主要发现
- 总体他汀使用率:亚裔25.5%、黑人20.0%、西班牙裔15.4%、白人27.9%。
- 最高风险层(≥20%)他汀使用率:黑人23.8%(PR 0.90,95%CI 0.82-0.98 vs 白人)、西班牙裔23.9%(PR 0.90,95%CI 0.81-0.99 vs 白人)。
- 在每个种族和民族组内,他汀使用率随ASCVD风险层升高呈梯度增加。
- 常规医疗可及性和医疗保险与黑人、西班牙裔和白人成人更高的他汀使用显著相关。
- 他汀使用率随时间推移按种族和民族或ASCVD风险层无有意义变化。
临床怎么用
- 临床中应关注黑人和西班牙裔成人他汀一级预防使用不足的问题。
- 评估患者医疗可及性和保险状态可能有助于改善他汀使用公平性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The burden of atherosclerotic cardiovascular disease (ASCVD) in the US is higher among Black and Hispanic vs White adults. Inclusion of race in guidance for statin indication may lead to decreased disparities in statin use. OBJECTIVE: To evaluate prevalence of primary prevention statin use by race and ethnicity according to 10-year ASCVD risk. DESIGN, SETTING, AND PARTICIPANTS: This serial, cross-sectional analysis performed in May 2022 used data from the National Health and Nutrition Examination Survey, a nationally representative sample of health status in the US, from 2013 to March 2020 (limited cycle due to the COVID-19 pandemic), to evaluate statin use for primary prevention of ASCVD and to estimate 10-year ASCVD risk. Participants aged 40 to 75 years without ASCVD, diabetes, low-density lipoprotein cholesterol levels 190 mg/dL or greater, and with data on medication use were included. EXPOSURES: Self-identified race and ethnicity (Asian, Black, Hispanic, and White) and 10-year ASCVD risk category (5%-<7.5%, 7.5%-<20%, ≥20%). MAIN OUTCOMES AND MEASURES: Prevalence of statin use, defined as identification of statin use on pill bottle review. RESULTS: A total of 3417 participants representing 39.4 million US adults after applying sampling weights (mean [SD] age, 61.8 [8.0] years; 1289 women [weighted percentage, 37.8%] and 2128 men [weighted percentage, 62.2%]; 329 Asian [weighted percentage, 4.2%], 1032 Black [weighted percentage, 12.7%], 786 Hispanic [weighted percentage, 10.1%], and 1270 White [weighted percentage, 73.0%]) were included. Compared with White participants, statin use was lower in Black and Hispanic participants and comparable among Asian participants in the overall cohort (Asian, 25.5%; Black, 20.0%; Hispanic, 15.4%; White, 27.9%) and within ASCVD risk strata. Within each race and ethnicity group, a graded increase in statin use was observed across increasing ASCVD risk strata. Statin use was low in the highest risk stratum overall with significantly lower rates of use among Black (23.8%; prevalence ratio [PR], 0.90; 95% CI, 0.82-0.98 vs White) and Hispanic participants (23.9%; PR, 0.90; 95% CI, 0.81-0.99 vs White). Among other factors, routine health care access and health insurance were significantly associated with higher statin use in Black, Hispanic, and White adults. Prevalence of statin use did not meaningfully change over time by race and ethnicity or by ASCVD risk stratum. CONCLUSIONS AND RELEVANCE: In this study, statin use for primary prevention of ASCVD was low among all race and ethnicity groups regardless of ASCVD risk, with the lowest use occurring among Black and Hispanic adults. Improvements in access to care may promote equitable use of primary prevention statins in Black and Hispanic adults.
引用
- Jacobs JA, Addo DK, Zheutlin AR, et al. Prevalence of Statin Use for Primary Prevention of Atherosclerotic Cardiovascular Disease by Race, Ethnicity, and 10-Year Disease Risk in the US: National Health and Nutrition Examination Surveys, 2013 to March 2020. JAMA Cardiol. 2023. PMID: 36947031. doi:10.1001/jamacardio.2023.0228
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。